A large registry study shows borderline risk with one treatment.
Several multiple sclerosis (MS) disease-modifying therapies (DMTs) have been associated with increased risk for cancer. Investigators used the national health registry in Sweden to evaluate the risks for invasive cancer associated with rituximab (an anti-CD20 antibody used off-label for MS), fingolimod, and natalizumab. The analysis included 6136 patients with MS matched to 37,801 people without MS (general population).
The incidence rate for any invasive cancer per 10,000 person-years was 34.4 for rituximab, 44 for fingolimod, 26 for natalizumab, and 31 for those without MS. After adjusting for baseline characteristics among MS patients, the hazard ratio for invasive cancer compared with the general population was 0.85 with rituximab (95% c…
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)